FGF23 and chronic kidney disease: Tomohiro et al. continued the research in this field using a deoxycorticosterone acetate (DOCA)-salt mouse model with mild chronic kidney disease, hypertension, and HF with preserved ejection fraction, which was treated with continuous intravenous FGF23.